13G Filing: Biotechnology Value Fund LP and Alpine Immune Sciences Inc. (ALPN)

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Biotechnology Value Fund 0 0 277,314 277,314 2.0%
Biotechnology Value Fund II 0 0 179,272 179,272 1.3%
Biotechnology Value Trading Fund OS 0 0 50,452 50,452 Less%
BVF Partners OS Ltd 0 0 50,452 50,452 Less%
BVF Partners 0 0 661,200 661,200 4.8%
BVF Inc 0 0 661,200 661,200 4.8%
Mark N. Lampert 0 0 661,200 661,200 4.8%

Page 1 of 13 – SEC Filing

 UNITED STATES

SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c),
AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No. 3)1

Alpine Immune Sciences, Inc. (formerly known as Nivalis Therapeutics, Inc.)

 (Name of Issuer)

Common Stock, par value $0.001 per share

 (Title of Class of Securities)

02083G100

 (CUSIP Number)

July 24, 2017

 (Date of Event Which Requires Filing of this
Statement)

Check the appropriate box
to designate the rule pursuant to which this Schedule is filed:

   Rule 13d-1(b)
 ☒  Rule 13d-1(c)
   Rule 13d-1(d)

1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Follow Alpine Immune Sciences Inc. (NASDAQ:ALPN)